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of folates in humans.1 Homocysteine is formed 
in the metabolism of methionine (an amino acid 
necessary for the proper functioning of the body, 
supplied in animal proteins), and then is con‑
verted back to methionine in a reaction cat‑
alyzed by methionine synthase, whose coen‑
zyme is 5 ‑methyltetrahydrofolate (the product 
of the MTHFR ‑catalyzed reaction). S ‑adenosyl‑
methionine is formed from methionine, consti‑
tuting the main source of methyl groups used 
in the synthesis of nucleic acids, many proteins, 
and lipid neurotransmitters.2 Homocysteine is 
finally transformed in a transsulfuration reac‑
tion involving cystathionine β ‑synthase to cys‑
teine and excreted in the urine (FIGURE 1). The de‑
crease in MTHFR activity promotes an increase 
in total homocysteine (tHcy) in the blood, espe‑
cially in folate deficiency.
The MTHFR enzyme is encoded by the gene 
MTHFR located on chromosome 1 (1p36.22, OMIM 
607093, NM_005957). The 2 most common con‑
genital MTHFR polymorphisms in the white pop‑
ulation are MTHFR 677C>T and MTHFR 1298A>C.
MTHFR 677C>T polymorphism In carriers of 
the  MTHFR 677C>T polymorphism (new 
Introduction The widespread availability of ge‑
netic tests in the diagnosis of thrombophilia 
(a disorder involving the propensity for throm‑
boembolic events) has contributed to their fre‑
quent hasty ordering and inappropriate inter‑
pretation. Fear of thrombosis prompts patients 
and doctors to perform a panel of genetic tests 
involving the detection of mutations of varying 
significance and frequency. Misinterpreted results 
are often the basis for the unjustified initiation 
of anticoagulant therapy or thromboprophylax‑
is, which can provoke bleeding. This expert opin‑
ion issued by the Hemostasis Group of the Polish 
Society of Hematologists and Transfusiologists 
(Polskie Towarzystwo Hematologów i Transfuz‑
jologów) addresses the validity of determining 
the 2 most common MTHFR gene mutations.
5,10 ‑methylenetetrahydrofolate reductase 
(MTHFR, EC 1.5.1.20) is an enzyme from the 
class of oxidoreductases, involved, among oth‑
ers, in the  regulation of homocysteine con‑
centration. This enzyme is necessary in the re‑
methylation of homocysteine to methionine 
(FIGURE 1). It is also responsible for the conver‑
sion of 5,10 ‑methylenetetrahydrofolate to 
5 ‑methyltetrahydrofolate, the basic active form 
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also contribute to a low degree of hyperhomocys‑
teinemia, especially methotrexate (routine sup‑
plementation of folic acid is recommended in 
such patients). Vitamin B group and folic acid re‑
duce homocysteine levels by approximately 25%.
Concentrations of homocysteine exceeding 
100 µmol/l are found very rarely, and they are 
usually caused by very rare genetic mutations 
of cystathionine β ‑synthase, causing genetical‑
ly determined disease, homocystinuria (in Po‑
land several dozen cases), or other diseases, es‑
pecially end ‑stage renal disease. Homocystinuria, 
usually diagnosed in childhood or adolescence, 
is manifested by bone disorders, vision defects, 
and neurological disorders, and is also associated 
with an increased risk of premature atheroscle‑
rosis (especially stroke) and venous thrombosis.
To date, homocysteine levels have been stud‑
ied in more than 600 disease entities—from mi‑
graine and autism to osteoporosis—and most 
commonly slightly increased levels were found 
in these observational reports.
In Poland, in many centers, especially private 
ones, it is usually recommended to pay for deter‑
mination of the gene variants encoding MTHFR, 
and more specifically 2 common polymorphisms 
677C>T (665C>T) and 1298A>C (1286A>C). In‑
dications that prompt doctors to order such tests 
are usually: 1) recurrent or unprovoked (trauma, 
surgery, hormonal contraception, pregnancy, etc) 
events of venous thrombosis or pulmonary embo‑
lism; 2) obstetric complications, most often recur‑
rent miscarriages or even a single pregnancy loss, 
most often in the first trimester of pregnancy; 
3) sometimes only at the request of the patient.
This statement aims to briefly present the cur‑
rent state of knowledge on the MTHFR gene mu‑
tations and their relationship to obstetric compli‑
cations and thromboembolic events as well as in‑
dications for genetic testing for these mutations.
Relationship between total homocysteine and MTHFR 
gene polymorphisms versus cardiovascular disease 
and venous thrombosis Retrospective studies 
conducted in the 1980s have shown an increased 
incidence of homocysteine levels in the range of 
15 to 30 µmol/l and MTHFR 677C>T polymor‑
phism in the presence of concurrent folate de‑
ficiency in patients after myocardial infarction, 
stroke, and with coronary artery disease as well 
as with a history of venous thromboembolism 
(VTE), that is, deep vein thrombosis and / or 
pulmonary embolism.3-5 Meanwhile, prospec‑
tive studies conducted in the next decade re‑
vealed that these correlations are weak or even 
nonexistent, which was best demonstrated by 
the results of a multicenter study published in 
2002.6 Already in 2010, the American College of 
Cardiology and the American Heart Association 
made clear statements against the determina‑
tion of homocysteine  in the assessment of car‑
diovascular risk, recognizing hyperhomocyste‑
inemia as an insignificant risk factor on the lev‑
el of public health.7
nomenclature, c.665C>T, where “c” stands for 
coding DNA as the reference sequence; the terms 
C677T or C665T are no longer recommended; 
rs1801131 according to the Single Nucleotide Poly‑
morphism Database), there is a cytosine (C) to 
thymine (T) transition at the nucleotide position 
of 677 in exon 4 of the MTHFR gene (according 
to the new nomenclature, 665), and as a conse‑
quence, a change of alanine to valine at amino 
acid 222 of this protein (p.Ala222Val). This het‑
erozygous polymorphism reduces MTHFR ac‑
tivity by 40% (CT variant, MTHFR c. [665C>T]; 
[665C =]) and 70% in homozygous form (TT vari‑
ant, MTHFR c. [665C>T], [665C>T]). The CT vari‑
ant occurs in 20% to 40% of the white population 
and 1% to 4% of most other ethnicities. The TT 
variant occurs in about 10% of the general pop‑
ulation in Europe.
MTHFR 1298A>C polymorphism In carriers of 
the MTHFR 1298A>C polymorphism (new no‑
menclature, c.1286A>C, where “c” stands for 
coding DNA as the reference sequence; the term 
A1298C is no longer recommended; rs1801133 ac‑
cording to the Single Nucleotide Polymorphism 
Database), there is an adenine (A) to cytosine 
(C) transversion at position 1298 of the MTH-
FR gene (according to the new nomenclature, 
1286) and, as a consequence, a change of gluta‑
mine to alanine at amino acid 429 of this pro‑
tein (p.Glu429Ala). This polymorphism, found 
in 8% to 15% of the general white population 
(Asians, 1% to 4%), causes a less pronounced re‑
duction of MTHFR activity than in the MTHFR 
677C>T mutation, that is, by 10% in a heterozy‑
gous form (MTHFR c. [1298A>C]; [1298A =]) and 
by 40% in a homozygous form (variant CC; MTH-
FR c. [1298A>C]; [1298A>C]).
The decrease in MTHFR activity is more pro‑
nounced in people who are combined heterozy‑
gotes, that is, those who have the 677C>T vari‑
ant in one allele of the MTHFR gene simultane‑
ously and the 1298A>C variant in the other allele 
(recommended MTHFR c. [665C>T]; [1298A>C]).
The carriership of hetero‑ or homozygous vari‑
ants of MTHFR polymorphisms is associated with 
a genetically determined predisposition to in‑
creased blood levels of homocysteine. Such peo‑
ple are more often found to have mild hyperho‑
mocysteinemia—most often their fasting plasma 
levels are less than 30 µmol/l in the case of di‑
etary folate deficiency (mainly from green leafy 
vegetables) (FIGURE 1).
A  homocysteine concentration exceeding 
15 µmol/l is an indicator of hyperhomocystein‑
emia, which is considered to be mild in the range 
from 15 to 30 µmol/l (>95% of cases). It is es‑
timated that this form occurs in 5% to 7% of 
the general population, less often in people sup‑
plementing folate. In addition to a diet rich in an‑
imal protein (eggs, cheese, meat, etc) with a low 
supply of folate, hypothyroidism, chronic kidney 
disease, hypertension, obesity, diabetes, as well 
as smoking and chronic intake of certain drugs 
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in the panel of tests for congenital thrombophil‑
ia, that is, a genetically determined abnormal‑
ity increasing the risk of VTE. The presence of 
these polymorphisms does not increase the risk 
of VTE and its recurrence, nor does it contribute 
to changes or prolongation of the anticoagulant 
therapy. The same applies to other frequently 
commercially commissioned genetic tests, such 
as the factor V gene H2 variant and the 4G / 5G 
polymorphism (rs1799889) of the plasminogen 
activator inhibitor type 1 (PAI ‑1) gene.
An increased risk of VTE is observed in individ‑
uals with the factor V Leiden mutation (rs6025; 
5% of Poles) and prothrombin gene 20210A mu‑
tation (rs1799963; 3% of Poles), especially in 
the presence of additional prothrombotic fac‑
tors, such as the use of hormonal contraceptives, 
trauma, or surgery.
In light of these data, all scientific societies ad‑
vise against determination of homocysteine and 
MTHFR polymorphisms in the evaluation the VTE 
Significantly higher tHcy levels and a more 
frequent occurrence of the MTHFR 677C>T vari‑
ant were recorded in patients after a VTE inci‑
dent.8,9 These relationships have disappeared in 
the population on a diet high in folate and B vi‑
tamins, especially in the United States, where 
since January 1998, folic acid is added to cereal 
products. Already in years from 2005 to 2010, 
prospective studies were published, which con‑
vincingly documented the lack of a relationship 
between the development of VTE and T allele 
and C allele carriership, respectively, for MTHFR 
677C>T and 1298A>C polymorphisms.10,11 Fur‑
thermore, large clinical trials assessing whether 
the use of vitamin B group to reduce homocys‑
teine levels lowers the risk of a first or recurrent 
VTE event have shown that, despite a 25% re‑
duction in homocysteine levels, the risk of VTE 
is unchanged.12,13
Therefore, experts agree that the determina‑
tion of MTHFR mutations should not be included 
FIGURE 1 Methionine and homocysteine metabolism in humans (simplified scheme). Methionine (contained in proteins of animal origin) is converted 
to S ‑adenosylmethionine, an important source of methyl groups in the synthesis of various biologically active substances, including nucleic acids. 
Homocysteine is formed in humans only from methionine, which is first transformed into S ‑adenosyl homocysteine. Methionine recovery occurs on 
2 pathways. One requires methylenetetrahydrofolate reductase (MTHFR) activity, which is responsible for converting 5,10 ‑methylenetetrahydrofolate to 
5 ‑methyltetrahydrofolate, and its methyl group in the reaction catalyzed by methionine synthase in the presence of vitamin B12 leads to the formation of 
methionine. Folate (derived in the diet mainly from green leafy vegetables) in the enzymatic reaction is transformed to tetrahydrofolate and then to 
5,10 ‑methylenetetrahydrofolate in a reaction catalyzed by serine hydroxymethyltransferase (SHMT). An alternative pathway is the reaction catalyzed 
by betaine ‑homocysteine methyltransferase in the presence of betaine mainly formed from choline. In the process of homocysteine elimination from 
the body, cystathionine is formed in the reaction catalyzed by cystathionine β ‑synthase, and the final product excreted in the urine is cysteine.
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1 Studies of variants c.677C>T and c.1298A>C 
of the MTHFR gene are not justified in the search 
for the causes of recurrent miscarriages, regardless 
of the stage of pregnancy in which such complica‑
tions occurred.
2 Evaluation of these polymorphisms are not jus‑
tified in diagnostics aimed at assessing the risk of 
developmental disorders of the central nervous sys‑
tem (brain and / or neural tube) in offspring, as well 
as other developmental defects.
3 In women planning to have children, in order 
to reduce the risk of central nervous system de‑
fects, a standard prophylactic dose of folic acid of 
0.4 mg/d should be used, regardless of the absence 
or presence of c.677C>T and / or c.1298A>C MTH-
FR polymorphism in the MTHFR gene if such a test 
has been performed.
4 In the prophylaxis of fetal central nervous sys‑
tem defects, its active metabolites may also be used 
together with folic acid, irrespective of the absence 
or presence of c.677C>T and / or c.1298A>C MTH-
FR gene polymorphic variants.
5 In the prevention of central nervous system de‑
fects in women who have previously given birth 
to a child with such a defect, a higher dose of folic 
acid in the amount of 4 to 5 mg (5 mg tablets most 
commonly available on the market) should be used 
with the possibility of using active folic acid me‑
tabolites, independently from the absence or pres‑
ence of c.677C>T and / or c.1298A>C polymorphic 
variants in the MTHFR gene, if such a test has been 
performed.
6 Evaluation of c.677C>T and c.1298A>C variants 
of the MTHFR gene are not justified in testing for 
hereditary thrombophilia.
7 In patients who previously had the presence of 
c.677C>T and / or c.1298A>C variants in the MTH-
FR gene, but no clinical signs of thrombophilia were 
observed, anticoagulation (low ‑molecular ‑weight 
heparin or acetylsalicylic acid) should not be rec‑
ommended.
8  The analysis of polymorphic variants c.677C>T 
and c.1298A>C of the MTHFR gene for cancer pre‑
disposition should not be ordered.21
After reviewing the current recommenda‑
tions of scientific societies and available liter‑
ature, the experts of the Hemostasis Group of 
the Polish Society of Hematologists and Transfu‑
siologists in cooperation with a national consul‑
tant in clinical genetics, Professor Maria Sąsiadek 
recommend the following:
1 MTHFR 677C>T and MTHFR 1298A>C gene 
polymorphisms should not be ordered in patients 
after obstetric complications, as in patients with 
an arterial or venous thrombotic event.
2 The management of women planning preg‑
nancy or being pregnant who have detected MTH-
FR 677C>T and 1298A>C gene polymorphisms is 
the same as if these variants were absent.
3 First ‑degree relatives of persons in whom 
polymorphisms of the MTHFR 677C>T and MTH-
FR 1298A>C polymorphisms have been detected 
should not be tested for carrying these mutations.
risk, considering that these tests should not be in‑
cluded in the diagnosis of thrombophilia.2
Relationship between homocysteine concentration 
and MTHFR polymorphisms and pregnancy complica-
tions, including miscarriages Higher levels of ho‑
mocysteine have been found in pregnant wom‑
en with preeclampsia, premature placental abor‑
tion, and miscarriage. Currently, the prevalent 
view is that a slight increase in blood homocys‑
teine levels after miscarriage is a consequence, 
not a cause of pregnancy loss.14 Already at the 
beginning of the 21st century, meta ‑analyses of 
observational studies clearly showed that Cau‑
casian women who are homozygous for the T al‑
lele of the MTHFR 677C>T polymorphism are not 
at a greater risk of recurrent miscarriages than 
women with the CT or CC variant of this gene. 
Similarly, no such relationship was detected in 
carriers of the C allele variant MTHFR 1298A>C 
polymorphism.15
As a consequence, for more than 10 years, no 
scientific society has recommended the determi‑
nation of blood homocysteine levels or MTHFR 
polymorphisms in women following recurrent 
miscarriages (including the American College of 
Obstetricians and Gynecologists and the Nation‑
al Society of Genetic Counselors).14,16
Currently, to reduce the risk of developing neu‑
ral tube defects, it is recommended to take mul‑
tivitamin preparations containing 0.4 mg of fo‑
lic acid before planned pregnancy.17 Higher doses 
should be considered in women with a previous 
fetal neural tube defect during pregnancy. Cur‑
rently, it is not recommended to increase the dose 
of folic acid in pregnant women only on the basis 
of the detection of such a common genetic vari‑
ant as MTHFR 677C>T.18,19
There is also no convincing data that other 
forms of folic acid, including methylated folates, 
are more effective than the most commonly used 
synthetic preparation in increasing blood folate 
and reducing homocysteine levels,20 therefore 
other forms of this vitamin should not be rou‑
tinely recommended in pregnant women.
Testing for MTHFR polymorphisms is not rec‑
ommended for the assessment of thromboem‑
bolic risk or for the diagnosis of recurrent mis‑
carriages by the American College of Medical Ge‑
netics, the American Academy of Family Physi‑
cians, and American College of Obstetricians and 
Gynecologists.2,14
American College of Obstetricians and Gyne‑
cologists does not recommend tHcy or MTHFR 
mutation testing because there was no relation‑
ship between the MTHFR 677C>T polymorphism 
and obstetrical complications, including any in‑
crease in the risk of VTE during pregnancy.14
The position paper prepared by experts of 
the Polish Society of Human Genetics and the Pol‑
ish Society of Gynecologists and Obstetricians on 
testing for MTHFR gene variants published in 
2017 is consistent with other guidelines and con‑
tains the following recommendations21:
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15 Cao Y, Xu J, Zhang Z, et al. Association study between methylenetetra‑
hydrofolate reductase polymorphisms and unexplained recurrent pregnancy 
loss: a meta ‑analysis. Gene. 2013; 514: 105‑111. 
16 Laurino MY, Bennett RL, Saraiya DS, et al. Genetic evaluation and coun‑
seling of couples with recurrent miscarriage: recommendations of the Na‑
tional Society of Genetic Counselors. J Genet Couns. 2005; 14: 165‑181. 
17 American Academy of Pediatrics. Folic acid for the prevention of neu‑
ral tube defects. Committee on Genetics. Pediatrics. 1999; 104: 325‑327. 
18 Yang Y, Luo Y, Yuan J, et al. Association between maternal, fetal and 
paternal MTHFR gene C677T and A1298C polymorphisms and risk of re‑
current pregnancy loss: a comprehensive evaluation. Arch Gynecol Obstet. 
2016; 293: 1197‑1211. 
19 Zhang T, Lou J, Zhong R, et al. Genetic variants in the folate pathway 
and the risk of neural tube defects: a meta ‑analysis of the published litera‑
ture. PLoS One. 2013; 8: e59570. 
20 Lamers Y, Prinz ‑Langenohl R, Moser R, Pietrzik K. Supplementation with 
[6S]‑5 ‑methyltetrahydrofolate or folic acid equally reduces plasma total ho‑
mocysteine concentrations in healthy women. Am J Clin Nutr. 2004; 79: 
473‑478. 
21 Moczulska H, Pesz K, Gach A, et al. The position paper of experts from 
the Polish Society of Human Genetics and the Polish Society of Gynecolo‑
gists and Obstetricians regarding the commissioning and interpretation of 
test results for genetic variants in the MTHFR gene [in Polish]. Ginekol Peri‑
natol Prakt. 2017; 2: 234‑238.
4 Genetic evaluation including, in addition to 
MTHFR gene polymorphism testing, identification 
of mutations of other genes associated with methi‑
onine metabolism should be considered to confirm 
or exclude homocystinuria in the presence of high 
tHcy, that is, above 100 md/l, in fasting plasma.
In summary, the testing for MTHFR polymor‑
phisms should not be recommended in women 
after obstetric complications or in patients who 
have had venous or arterial thromboembolic 
events. Detection of these polymorphisms should 
not change clinical management, including indi‑
cations for thromboprophylaxis. Performing such 
genetic tests with expenses covered from public 
funds by patients themselves is unnecessary and 
exposes patients to the inconvenience associat‑
ed with blood drawing and concerns about mis‑
interpretation of the results.
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